RT Journal Article
SR Electronic
T1 Evaluating the effects of second-dose vaccine-delay policies in European countries: A simulation study based on data from Greece
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257486
DO 10.1101/2021.05.19.21257486
A1 Barmpounakis, P.
A1 Demiris, N.
A1 Kontoyiannis, I.
A1 Pavlakis, G.
A1 Sypsa, V.
YR 2021
UL http://medrxiv.org/content/early/2021/11/20/2021.05.19.21257486.abstract
AB The results of a simulation-based evaluation of several policies for vaccine rollout are reported, particularly focusing on the effects of delaying the second dose of two-dose vaccines. In the presence of limited vaccine supply, the specific policy choice is a pressing issue for several countries worldwide, and the adopted course of action will affect the extension or easing of non-pharmaceutical interventions in the next months. We employ a suitably generalised, age-structure, stochastic SEIR (Susceptible → Exposed → Infectious → Removed) epidemic model that can accommodate quantitative descriptions of the major effects resulting from distinct vaccination strategies. The different rates of social contacts among distinct age-groups (as well as some other model parameters) are informed by a recent survey conducted in Greece, but the conclusions are much more widely applicable. The results are summarised and evaluated in terms of the total number of deaths and infections as well as life years lost. The optimal strategy is found to be one based on fully vaccinating the elderly/at risk as quickly as possible, while extending the time-interval between the two vaccine doses to 12 weeks for all individuals below 75 years old, in agreement with epidemic theory which suggests targeting a combination of susceptibility and infectivity. This policy, which is similar to the approaches adopted in the UK and in Canada, is found to be effective in reducing deaths and life years lost in the period while vaccination is still being carried out.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNon applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Non applicableI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code for this project is available at https://github.com/pbarmpounakis/Evaluating-the-effects-of-vaccine-rollout-policies-in-European-countries-A-simulation-study https://github.com/pbarmpounakis/Evaluating-the-effects-of-vaccine-rollout-policies-in-European-countries-A-simulation-study